Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

অনুরূপ উপাদানগুলি

• Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
  অনুযায়ী: Traboulsee, Anthony, অন্যান্য
  প্রকাশিত: (2018)
• Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study
  অনুযায়ী: Traboulsee, Anthony, অন্যান্য
  প্রকাশিত: (2018)
• Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
  অনুযায়ী: Camu, William, অন্যান্য
  প্রকাশিত: (2010)
• Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
  অনুযায়ী: Arnold, Douglas L., অন্যান্য
  প্রকাশিত: (2016)
• A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon β-1a
  অনুযায়ী: Al Jumah, Mohammed, অন্যান্য
  প্রকাশিত: (2021)